HeartMate® II Clinical Trial at California Pacific

For many patients with severe heart disease, heart transplantation is not always an option and donor hearts continue to be scarce. Today mechanical circulatory assist devices are expanding the treatment options for patients with end-stage heart disease. Recent clinical research studies have shown that these devices can improve the quality and length of life for many patients.

One of only 27 Heart Centers Nationwide

California Pacific Medical Center is one of only 27 heart centers nationwide participating in a new life-saving clinical trial utilizing Thoratec Corporation’s HeartMate® II Left Ventricular Assist System (LVAS). HeartMate II is conveniently small, about the size of a “D” cell battery, and therefore, it is suitable for a wider range of patients. This quiet, lightweight device, weighing only 12 ounces, is designed to meet the needs of patients requiring long-term cardiac support. Similar to other ventricular assist devices on the market, the HeartMate II takes over the function of the damaged heart and restores hemodynamics.

In December 2004, the pilot phase of the clinical trial was completed with promising early results. Many patients implanted with the HeartMate II during the pilot phase returned home and resumed an active life. The larger pivotal trial phase has commenced and comprises of two study arms that include patients who are eligible for cardiac transplantation (bridge-to-transplant) as well as those who are ineligible (destination therapy).

California Pacific Medical Center Research Institute

California Pacific’s Research Institute is currently enrolling patients, who are not responding to conventional therapy, in this clinical trial. Learn more about our clinical trials.